Application of microbial metabolite in tumor immune response and microbial metabolite screening method
By constructing a screening system for PD-1/SHP-2 pathway signal transduction, intestinal microbial metabolites such as glycine deoxycholic acid and taurocholic acid were screened out, which solved the problem of insufficient immune response in colorectal cancer in existing technologies and achieved enhanced treatment effects for colorectal cancer.
Patent Information
- Application Number
- CN202510929567.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-07
- Publication Date
- 2025-11-14
AI Technical Summary
In existing technologies, there are relatively few types of gut microbial metabolites that affect the immune response to colorectal cancer, and their effects are relatively weak. More effective metabolites need to be screened out to enhance the efficacy of colorectal cancer immunotherapy.
A screening system based on PD-1/SHP-2 pathway signal transduction was constructed. By binding firefly luciferase to PD-1/SHP-2, intestinal microbial metabolites such as glycodeoxycholic acid (GDCA) and taurocholic acid (TCA) were screened out to inhibit T cell function and promote tumor growth. Effective metabolites were screened out by luciferase activity assay.
A reliable, rapid, and effective screening and evaluation system was established, and gut microbial metabolites that affect the PD-1 signaling pathway were discovered and validated, which enhanced the immune response to colorectal cancer and provided experimental evidence for the treatment of colorectal cancer.